A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults

Completed · Phase 2 · Has a placebo group

Conditions studied: Keloid

In brief

To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision.

Key facts

Study ID

NCT02079168

Run by

RXi Pharmaceuticals, Corp.

People needed

16

Starts

2014-03-01

Expected to finish

2016-03-01

Last updated by the study team

2016-06-14

Who can join

Age: 21 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adults, 21-55 years of age.
• Two keloids of approximately similar size and anatomical location on the earlobe, neck, or torso.
• Keloids to be excised must have been present for > 1 year.

You may not qualify if…

• Use of tobacco or nicotine-containing products
• Pregnant or lactating
• Post-menopausal or full hysterectomy

Where it is running

• Study site — Miami, Florida, United States
• Study site — St Louis, Missouri, United States
• Study site — San Cristobal, Dominican Republic

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.